Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis

Authors Information
Article Notes and Dates
To Cite : Aalaei-Andabili S H, Behnava B, Salimi S, Sharafi H, Alavian S M. et al. Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis, Hepat Mon. 2014 ;14(3):e15895. doi: 10.5812/hepatmon.15895.
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Montella M, Crispo A, Giudice A. HCC, diet and metabolic factors: Diet and HCC. Hepat mon. 2011; 11(3): 159-62[PubMed]
  • 2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13(1): 34-41[DOI][PubMed]
  • 3. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6): 580-93[DOI][PubMed]
  • 4. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat mon. 2010; 10(2): 121-31[PubMed]
  • 5. Abenavoli L, Mazza M, Almasio PL. The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepat mon. 2011; 11(4): 240-6[PubMed]
  • 6. Alavian SM, Tabatabaei SV, Behnava B, Mahboobi N. Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis. Hepat mon. 2011; 11(8): 612-9[PubMed]
  • 7. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int. 2011; 31 Suppl 1: 29-35[DOI][PubMed]
  • 8. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 9. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genet. 2009; 41(10): 1100-4[DOI][PubMed]
  • 10. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 11. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45, 1345.e1-7[DOI][PubMed]
  • 12. Sibbing B, Nattermann J. Hepatitis C virus infection and genetic susceptibility to therapy. JGLD. 2011; 20(4): 397-406[PubMed]
  • 13. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011; 54(3): 415-21[DOI][PubMed]
  • 14. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjoro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology. 2011; 53(3): 746-54[DOI][PubMed]
  • 15. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010; 52(1): 33-7[DOI][PubMed]
  • 16. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol. 2011; 31(5): 891-9[DOI][PubMed]
  • 17. Glynn L. EBLIP Critical Appraisal Checklist. 2011;
  • 18. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008; 8: 79[DOI][PubMed]
  • 19. Aalaei-Andabili SH, Alavian SM. Non-negligible Steps for Reliable Meta-Analysis. Lancet ID. 2012;
  • 20. El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, et al. Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon. 2012; 12(4): 271-7[DOI][PubMed]
  • 21. Mahboobi N, Behnava B, Alavian SM. IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report. Hepat Mon. 2011; 11(5): 386-8[PubMed]
  • 22. Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A. 2011; 108(9): 3719-24[DOI][PubMed]
  • 23. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol. 2011; 55(3): 692-701[DOI][PubMed]
  • 24. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2012; 36(2): 91-103[DOI][PubMed]
  • 25. Pedergnana V, Abdel-Hamid M, Guergnon J, Mohsen A, Le Fouler L, Theodorou I, et al. Analysis of IL28B Variants in an Egyptian Population Defines the 20 Kilobases Minimal Region Involved in Spontaneous Clearance of Hepatitis C Virus. PLoS One. 2012; 7(6)[DOI][PubMed]
  • 26. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010; 139(5): 1586-92, 1592.e1[DOI][PubMed]
  • 27. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011; 55(6): 1195-200[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check